製薬大手は先進治療の研究開発に注力

ランク

会社

概要

製品ポートフォリオ

販売地域

開発

1.

バイエルAG

バイエルAGは、炭疽菌治療薬を含む幅広い疾患に対応する製品を提供する多国籍製薬・ライフサイエンス企業です。研究開発への取り組みは、炭疽菌の予防と治療の両方に対応する革新的な治療法の開発につながっています。バイエルはバイオテクノロジーと医薬品の専門知識を活かし、市場における主要プレーヤーとしての地位を確立しています。       

• シプロバイ
• アバロックス

北米、中東・アフリカ、ヨーロッパ、南米、アジア太平洋

2021年12月、バイエルは2030年までのサステナビリティへのコミットメントを推進するため、持続可能な健康製品に1億ユーロを投資します。この投資は、コンシューマーヘルス部門が患者の健康に関わる革新的な製品をさらに開発する上で役立ちます。

2.

ファイザー社

ファイザー社は、炭疽菌治療薬をはじめとする革新的な医薬品で知られる大手製薬会社です。ファイザー社の研究開発は、炭疽菌に対する新たな治療法の発見と既存の治療法の改良に重点を置いています。世界的なプレゼンスと医療へのコミットメントにより、同社は市場において重要な存在となっています。         

• レボフロキサシン
• シプロフロキサシン
• アンピシリン

アメリカ、中東・アフリカ、ヨーロッパ、アジア太平洋

In 2007, Pfizer Inc. acquired Coley Pharmaceutical Group, which developed AV7909, an anthrax vaccine candidate that combines BioThrax(R) with the immunostimulatory oligodeoxynucleotide compound CPG 7909 (VaxImmune(R)).

3.

Teva Canada Limited

Teva Canada Limited is a pharmaceutical company that offers a range of generic and specialty medicines, including treatments for anthrax. Teva's focus on providing affordable and accessible healthcare solutions makes it a key player in the global anthrax treatment market. The company's commitment to quality and innovation ensures that its anthrax treatments meet the highest standards of safety and efficacy.

• Cipro
• Levaquin
• Penbritin
• Ampicin
• ErythromycinTablets,USP

North America, Middle East and Africa, Europe, South America, Asia-Pacific

In May 2021, Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), launched its 250 mg and 500 mg strength generic Erythromycin tablets. These tablets are a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. Teva's generic Erythromycin tablets are indicated for treating various bacterial infections, including anthrax, a severe infectious disease caused by Bacillus anthracis.

4.

 Sanofi

 Sanofi is a global healthcare company that develops and manufactures a range of pharmaceutical products, including treatments for anthrax. Sanofi's research and development efforts focus on innovative therapies for anthrax, addressing the evolving needs of patients and healthcare providers. The company's commitment to improving global health makes it a significant player in the market.   

• Tavanic

North America, Europe, Asia-Pacific

Tavanic, a drug by Sanofi is used to treat various bacterial infections and is also used to treat anthrax (a rare but serious bacterial illness). It includes Levofloxacin, a quinolone antibiotic that inhibits bacterial DNA gyrase, an enzyme required for the replication, transcription, and repair of the DNA. Thus inhibits bacterial growth and treats bacterial infection.

5.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company that develops and manufactures a range of medicines, including treatments for anthrax. Takeda's expertise in biotechnology and pharmaceuticals enables it to develop innovative therapies for anthrax, addressing the complex challenges of the disease. The company's commitment to research and development makes it a key player.

• PREVPAC

North America, Europe, Asia-Pacific

In June 2018, Takeda Pharmaceutical Company Limited, a global biopharmaceutical company, was engaged in the development of Prevac, a vaccine used for anthrax. Prevac aims to prevent anthrax infection caused by the bacterium Bacillus anthracis and is intended for individuals at high risk of exposure, such as military personnel, laboratory workers, and specific emergency responders. To preserve the effectiveness of PREVPAC and other antibacterial drugs and minimize the development of drug-resistant bacteria, PREVPAC should be used exclusively for treating or preventing infections.